# COUR Pharmaceuticals Development Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cour-pharmaceuticals-development-co

- Industry: Biotechnology
- Headquarters: Skokie, US
- Website: www.courpharma.com
- Total disclosed funding: $155M
- Latest round: Series B (Jun 18, 2026)
- Investors on record: 8

## About

Based in Skokie, Illinois, US, and founded in 2015 by John J. Puisis (Founder and former President & CEO), COUR Pharmaceuticals Development Co., Inc. is a clinical-stage biotechnology company developing first-in-class, antigen-specific immune tolerance therapies to reprogram the immune system for immune-mediated diseases. Dannielle Appelhans currently serves as President and CEO.
Cour Pharmaceuticals Development Company, Inc. has developed a proprietary antigen-specific immune tolerance nanoparticle platform (CNP platform), designed to reprogram the immune system to induce tolerance to disease-driving antigens while preserving normal immune function. The company's product pipeline includes CNP-103, a biodegradable nanoparticle encapsulating four recombinant proteins covering more than 95% of antigens driving type 1 diabetes (T1D), currently in a Phase 1b/2a clinical trial and granted FDA Fast Track Designation; CNP-104, a biodegradable nanoparticle encapsulating PDC-E2 for the treatment of primary biliary cholangitis (PBC), granted FDA Fast Track and Orphan Drug Designations; CNP-106, an antigen-specific investigational therapeutic for myasthenia gravis, granted FDA Orphan Drug Designation; CNP-105, an investigational therapeutic for immune thrombocytopenia (ITP), designed to restore normal platelet levels; CNP-107, an antigen-specific investigational therapeutic for vitiligo; and CNP-108, a biodegradable nanoparticle encapsulating AAV protein for gene therapy and protein replacement applications. In partnered programs, the company is developing CNP-101/TAK-101, a biodegradable nanoparticle encapsulating gliadin proteins for the treatment of celiac disease, partnered with Takeda and granted FDA Fast Track Designation; and CNP-201, a biodegradable nanoparticle encapsulating peanut protein for the treatment of peanut allergy.
In June 2026, COUR Pharma raised USD 50 million in Series B funding. The round was led by Lumira Ventures and Roche Venture Fund, with participation from new investor Sanofi, Pfizer Ventures and existing investors Alpha Wave Ventures, Angelini Ventures, and T1D Fund: A Breakthrough T1D Venture.
The company's revenue is generated through strategic licensing and collaboration agreements, including upfront payments, developmental and regulatory milestone payments, and royalties on the future commercialization of its partnered therapies with Takeda and Ironwood Pharmaceuticals, in addition to funding from venture capital investment rounds.
As of June 2026, the company plans to use the Series B proceeds to advance the clinical development of CNP-103 through its Phase 1b/2a trial for type 1 diabetes, and to seek partners for the continued clinical development of CNP-104 for primary biliary cholangitis and CNP-106 for myasthenia gravis

## Funding rounds

- Series B, Jun 18, 2026, $50M — Roche Venture Fund, Pfizer Venture Investments, Sanofi, Alpha Wave Global, JDRF T1D Fund, Lumira Ventures, Angelini Ventures
- Series A, Jan 30, 2024, $105M — Roche Venture Fund, Alpha Wave Global, Bristol-Myers Squibb Company, JDRF T1D Fund, Lumira Ventures, Angelini Ventures

## Investors

- Roche Venture Fund (https://capitalatlas.ai/funds/roche-venture-fund) — Series A, Series B
- Alpha Wave Global (https://capitalatlas.ai/funds/alpha-wave-global) — Series A, Series B
- Bristol-Myers Squibb Company — Series A
- JDRF T1D Fund (https://capitalatlas.ai/funds/jdrf-t1d-fund) — Series A, Series B
- Lumira Ventures (https://capitalatlas.ai/funds/lumira-ventures) — Series A, Series B
- Angelini Ventures (https://capitalatlas.ai/funds/angelini-ventures) — Series A, Series B
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series B
- Sanofi — Series B